1α,25-Dihydroxyvitamin D₃ potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model

Yingyu Ma,¹ Wei-Dong Yu,¹ Pamela A. Hershberger,² Geraldine Flynn,¹ Rui-Xian Kong,¹ Donald L. Trump,² and Candace S. Johnson¹

Departments of ¹Pharmacology and Therapeutics and ²Medicine, Roswell Park Cancer Institute, Buffalo, New York and ³University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania

Abstract

1α,25-Dihydroxyvitamin D₃ (1,25D₃) exhibits antitumor activity in a variety of cancers including squamous cell carcinoma (SCC). Intrinsic resistance of SCC cells to cisplatin was observed and led to the investigation into whether 1,25D₃ sensitizes SCC cells to cisplatin. Pretreatment with 1,25D₃ followed by cisplatin enhanced growth inhibition in SCC cells compared with 1,25D₃ alone as assessed by cytotoxicity and in vitro clonogenic assays. In addition, 1,25D₃ sensitized SCC cells to cisplatin-mediated apoptosis. Treatment of tumor-bearing C3H mice with 1,25D₃ before cisplatin reduced clonogenic survival using in vivo excision clonogenic assay. These results were not observed in a 1,25D₃-resistant SCC variant, indicating the critical role of 1,25D₃ in sensitizing SCC cells to cisplatin. Further, a marked decrease in fractional tumor volume was observed when SCC tumor-bearing mice were treated with 1,25D₃ before cisplatin compared with either agent administered alone. Cisplatin has been shown to modulate p73 protein level in certain cancer cells. Our data showed that p73 level was not affected by cisplatin but increased by 1,25D₃ in SCC cells. Knocking down p73 by small interfering RNA protected SCC cells against 1,25D₃ and cisplatin-mediated clonogenic cell kill and apoptosis. Increasing p73 protein level by knocking down UFD2a, which mediates p73 degradation, promoted 1,25D₃ and cisplatin-mediated clonogenic cell kill. These results suggest that 1,25D₃ potentiates cisplatin antitumor activity in vitro and in vivo in a SCC model system possibly through p73 induction and apoptosis. The combination treatment may provide a more effective therapeutic regimen in cancer treatment.

Introduction

Vitamin D regulates diverse physiologic functions including calcium homeostasis, bone metabolism, cell differentiation, and immunity (1, 2). 1α,25-Dihydroxyvitamin D₃ (1,25D₃), the most active metabolite of vitamin D, inhibits the growth of several cancer types such as prostate, breast, colorectal, ovarian, and skin cancers (1, 2). 1,25D₃ is currently being evaluated, alone or in combination with other chemotherapeutic agents, in clinical trials for the treatment of several solid tumors (1, 3).

Cisplatin [cis-diammine-dichloro-platinum (II)] is a potent chemotherapeutic agent widely used for the treatment of a variety of cancers, including testicular, ovarian, cervical, and lung cancers and head and neck squamous cell carcinoma (SCC; refs. 4, 5). However, its effectiveness as an anticancer agent is limited by drug resistance and side effects including nephrotoxicity, emetogenesis, and neurotoxicity (6). Tumor resistance to cisplatin may be caused by insufficient DNA binding, increased DNA repair ability, bypass of DNA adducts, or impaired apoptosis (7). Hence, it will be beneficial if tumor cells can be sensitized to cisplatin treatment with a combination therapy.

DNA damage caused by cisplatin may induce the activation of tumor suppressor p53 (6, 8), which inhibits cell proliferation by promoting cell cycle arrest or apoptosis. The presence of wild-type p53 correlates to the sensitivity to cisplatin (6). Because p53 is frequently mutated or functionally impaired in human cancers, the status of a p53-related protein, p73, is considered to be an important determinant of cellular sensitivity to chemotherapeutic drugs.

p73 has significant homology to p53. p73 gene encodes multiple isoforms due to the usage of alternative promoters and the alternative splicing (9). Transcription of p73 gene from promoter P1 results in the isoforms containing a NH₂-terminal transactivation domain (TAp73), whereas the isoforms transcribed from promoter P2 are NH₂-terminal truncated and lack the transactivation domain (ΔNp73) (9). TAp73 is a transcription factor and regulates genes involved in cell cycle arrest and apoptosis and other cellular functions. Some genes are common targets of p53, such as Bax, Puma, and Noxa, whereas others are not regulated by p53. In contrast, ΔNp73 may serve as dominant-negative inhibitors of p53 family (10).
Unlike p53, p73 mutation is rare in human cancers (10). Loss of heterozygosity and methylation-mediated gene silencing are observed in many cancer types (10). In addition, p73 gene polymorphism is implicated in tumorigenesis (11). p73 protein expression is deregulated in many cancers (10, 11). Loss of p73 has been reported to associate with tumor progression and poor prognosis in several cancers (12–15). p73 loss triggers the conversion of keratinocytes to SCC (16). Although p73 knockout mice do not develop spontaneous tumors in the initial studies, mice heterozygous for p73 (p73+/−) or p63 (p63+/−) develop malignant tumors at high frequency (17). Moreover, higher tumor burden and metastasis are observed in p53+/−; p73+/− and p53−/−; p63−/− mice compared with p53+/− mice (17). These observations indicate p73 plays a role in tumor development.

We showed previously that 1,25D3 exerts antiproliferative effects in murine SCC cell line SCCVII/SF (18–20). These effects are mediated by the induction of cell cycle arrest and apoptosis (20, 21). We also showed that pretreatment with 1,25D3 enhances paclitaxel, cisplatin, or carboplatin-mediated antitumor activities (22–24). However, the mechanisms for 1,25D3-enhanced cisplatin antitumor effects remain unclear.

In the current study, we established a variant of SCC cell line, SCC-DR, which is resistant to 1,25D3 and thereby serves as a control to study the effects of 1,25D3. Further, we investigate the mechanisms of 1,25D3 and cisplatin-mediated growth inhibition, especially the role of p73 and apoptosis in SCC cells.

Materials and Methods

Materials
1,25D3 was a generous gift from Hoffmann-LaRoche. Cisplatin (Platinol-AQ) was obtained from Bristo-Myers Squibb. Anti-vitamin D receptor (VDR; sc-1008) and anti-phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2; sc-7383) were from Santa Cruz Biotechnology. Anti-caspase-3, anti-caspase-8, anti-caspase-9, anti-caspase-10, anti-phosphorylated Akt (Ser473), anti-Akt, anti-ERK1/2 (ERK1/2; sc-7383) were from Santa Cruz Biotechnology. Anti-caspase-3, anti-caspase-8, anti-caspase-9, anti-caspase-10, anti-phosphorylated Akt (Ser473), anti-Akt, anti-ERK1/2, and anti-p53 were from Cell Signaling Technology. Anti-p73 (IMG-246; clone 5B429) was from Imgenex. Anti-poly(ADP-ribose) polymerase and anti-p63 was from BD PharMingen. Anti-actin was from Calbiochem.

Cell Culture and Tumor Model Systems
Murine SCC (SCC VII/SF) is a moderately well differentiated SCC derived from a spontaneously arising tumor of the C3H mouse (25). SCC cells were maintained in 6- to 10-week-old female C3H/HeJ mice from The Jackson Laboratory. SCC cells were cultured in RPMI 1640 supplemented with 12% fetal bovine serum and 1% penicillin/streptomycin sulfate. The mice protocols used for in vivo excision clonogenic assays were approved by the Roswell Park Cancer Institutional Animal Care and Use Committee. The mice protocols used for tumor regrowth delay were approved by University of Pittsburgh Animal Care Committee according to USPHS guidelines.

Generation of SCC-DR Cells
SCC cells were continuously cultured in RPMI 1640/fetal bovine serum containing 10 nmol/L 1,25D3 for over 10 months until no cytotoxicity was observed on a light microscope. The resulting stable SCC-DR cell line was maintained in RPMI 1640/fetal bovine serum containing 10 nmol/L 1,25D3. For experiments, SCC-DR cells were plated in RPMI 1640/fetal bovine serum without 1,25D3 overnight and subjected to further treatment.

Trypan Blue Exclusion Assay
Cell viability was quantitatively assessed by trypan blue exclusion assay using Vi-CELL Series Cell Viability Analyzers (Beckman-Coulter).

Cytotoxicity Assay
Cytotoxicity was quantified by the released lactate dehydrogenase from the cytosol of damaged cells using Cytotoxicity Detection KitPLUS (lactate dehydrogenase) kit following the manufacturer’s protocol (Roche Applied Science).

In vitro Clonogenic Assay
SCC or SCC-DR cells were pretreated with ethanol or 10 nmol/L 1,25D3 for 24 h and then treated with 0.5 μg/mL cisplatin for 2 h or left untreated. Cisplatin was then washed away and 1,25D3 was replaced in the groups treated with 1,25D3. The in vitro clonogenic assays were done as described (23, 26).

In vivo Clonogenic Assay
The in vivo effects of 1,25D3 and cisplatin on clonogenic SCC cells were determined by in vivo excision clonogenic assay as described (22, 26–28). Briefly, C3H mice bearing 9-day SCC or SCC-DR tumors were treated in four groups (3–5 per group): saline, 1,25D3, cisplatin, or 1,25D3 and cisplatin combination. Mice were treated for 3 days with daily i.p. injection of saline or 0.625 μg/mouse 1,25D3. On day 3, mice also received i.p. injection of 3 mg/kg cisplatin. Twenty-four hours after the last injection, mice were sacrificed, and their tumors were excised. Clonogenic assays were done as described (26).

Tumor Regrowth Delay
SCC cells (4.5 × 103) were inoculated s.c. into the flank of the C3H mice. Studies were initiated when the tumors were palpable. Mice were treated in four groups (10 per group): saline, 1,25D3, cisplatin, or 1,25D3 and cisplatin combination. Mice were treated for 3 days with single, daily i.p. injections of saline or 0.25 μg/mouse 1,25D3. On day 3, mice also received a single i.p. injection of 6 mg/kg cisplatin. Tumor measurements were done as described (22).

Immunoblot Analysis
Cell lysates were prepared and immunoblot analysis was done as described previously (19, 21).

Apoptosis Assay: DNA Fragmentation ELISA
SCC cells were harvested and lysed, and DNA fragmentation was quantitatively evaluated by Cell Death Detection ELISAPLUS according to the manufacturer’s instructions as described (19, 21).

Real-time Quantitative Reverse Transcription-PCR
Total RNA from SCC cells was isolated using the RNasy Mini kit (Qiagen) according to the manufacturer’s
instructions. First-strand cDNA was synthesized from 1 μg total RNA using oligo(dT) primers (iScript cDNA synthesis kit; Bio-Rad). Gene quantification was done on an Applied Biosystems 7300 real-time system (Applied Biosystems) with standard thermal cycler conditions. TaqMan primers and probes for p73 and glyceraldehyde-3-phosphate dehydrogenase were purchased from Applied Biosystems. Relative gene expression was determined by the ΔΔ-C_T method.

Small Interfering RNA Transfection

Synthetic small interfering RNA (siRNA) siGENOME SMARTpool siRNAs (four individual siRNA pooled together) specific for p73, UFD2a, siCONTROL nonspecific siRNA (siRNA-NS), and DharmaFECT1 transfection reagent were from Dharmacon. SCC cells were transfected with 50 nmol/L siRNA-NS or siRNA against p73 or UFD2a for 24 h using DharmaFECT1 transfection reagent following the manufacturer’s protocol.

Statistics

Statistical significances between groups were determined by two-tailed student’s t test.

Results

Generation of 1,25D_3-Resistant SCC Cells

We showed previously that 1,25D_3 has antitumor effects in SCC cells (18–20). Cisplatin is widely used to treat patients with head and neck SCC with moderate success (29). Therefore, SCC cell line serves as an ideal model to study the effects of combination treatment with 1,25D_3 and cisplatin.

We showed previously that 1,25D_3 induces cell cycle arrest and apoptosis in SCC cells (19, 20, 30). However, only a small percentage of the cells responded to 1,25D_3. To have a better understanding on the effects of 1,25D_3 in SCC cells, we established a 1,25D_3-resistant variant of SCC, SCC-DR cell line, by continuously culturing SCC cells in medium containing 10 nmol/L 1,25D_3, the dose that has antiproliferative effects in SCC cells and is clinically achievable in man (19, 20, 30). To examine whether SCC-DR cells are resistant to the growth-inhibitory effects of 1,25D_3, SCC-DR cells or control parental SCC cells were treated with 10 or 500 nmol/L 1,25D_3 and subjected to in vitro clonogenic assay. The colony-forming capacity of SCC cells was greatly inhibited by 1,25D_3 (Fig. 1A). In contrast, the colony-forming capacity of 1,25D_3-treated SCC-DR cells was mostly intact (Fig. 1B).

To further characterize the cellular functions of SCC-DR cells, 1,25D_3-mediated transcriptional activity and apoptosis were examined. No induction of VDR was observed in SCC-DR cells until 1,000 nmol/L 1,25D_3 was used, whereas VDR was induced in SCC cells on 10 nmol/L 1,25D_3 treatment (Fig. 1B), suggesting that SCC-DR cells have compromised transcriptional activity of VDR. Additionally,
Pro-caspase-3 was readily cleaved in SCC cells with 10 nmol/L 1,25D₃ treatment, whereas it remained intact in SCC-DR cells (Fig. 1B), suggesting that SCC-DR cells are resistant to 1,25D₃-induced apoptosis. We showed previously that 1,25D₃ induces nongenomic activation (occurs within 5 min) of Akt and ERK1/2 in SCC cells (21). 1,25D₃ did not induce rapid activation of Akt in SCC-DR cells (Fig. 1C). Interestingly, 1,25D₃ activated ERK1/2 in SCC-DR cells at ~30 min (Fig. 1C), indicating the nongenomic signaling of 1,25D₃ is partially affected. Together, these results show that SCC-DR cells are resistant to 1,25D₃ treatment at several aspects; therefore, it may serve as a control model to study the effects of 1,25D₃ in sensitive cell lines.

**SCC and SCC-DR Cells Are Resistant to Cisplatin**

To examine whether cisplatin has cytotoxic effects in SCC or SCC-DR cells, the cells were treated with various doses (0-1 μg/mL) of cisplatin for 48 h and cell viability was assessed by trypan blue exclusion assay. Surprisingly, cisplatin had no cytotoxic effects in SCC and SCC-DR cells even at 1 μg/mL, suggesting they are resistant to cisplatin over the range of concentration tested (Fig. 2A).

1,25D₃ Sensitizes SCC Cells to Cisplatin Treatment

In vitro

We showed previously that 1,25D₃ and cisplatin have synergistic growth inhibition in SCC cells indicated by MTT assays (24). To further determine whether 1,25D₃ can sensitize SCC cells to cisplatin, two other methods were employed: cytotoxicity assay by measuring the released lactate dehydrogenase from damaged cells and the in vitro clonogenic assay. SCC or SCC-DR cells were pretreated with 10 nmol/L 1,25D₃ or vehicle control ethanol for 24 h followed by 0.5 μg/mL cisplatin or control medium for 2 h. Cytotoxicity was assessed after an additional 48 h of incubation. 1,25D₃ induced significant (P < 0.01) cytotoxicity in SCC cells (Fig. 2B). Cisplatin did not induce cytotoxicity; however, pretreatment of 1,25D₃ for 24 h followed by cisplatin resulted in enhanced cytotoxicity compared with 1,25D₃ alone, suggesting that 1,25D₃ sensitized SCC cells to cisplatin-induced cell killing (Fig. 2B). In contrast, cytotoxicity was not observed on any treatment in SCC-DR cells (Fig. 2B). The more sensitive clonogenic assay revealed that 1,25D₃ or cisplatin alone markedly inhibited the clonogenic capacity of SCC cells. The combination treatment had more profound effect than 1,25D₃ or cisplatin alone (Fig. 2C). These results suggest that 1,25D₃ potentiates cisplatin antiproliferative effects in SCC cells.

**1,25D₃ Promotes Cisplatin Antitumor Activity In vivo**

To evaluate whether 1,25D₃ also enhances the antiproliferative effects of cisplatin in vivo, the in vivo excision clonogenic assay was used. We showed previously that this assay is an indication of in vivo antitumor activity (23, 27, 28, 31, 32). SCC or SCC-DR tumor-bearing mice were treated with saline, 0.625 μg/d 1,25D₃ for 3 days, 3 mg/kg cisplatin on day 3, or the combination of 0.625 μg/d 1,25D₃ for 3 days and 3 mg/kg cisplatin on day 3. The combination of 1,25D₃ and cisplatin resulted in a significantly greater decrease in surviving fraction compared with 1,25D₃ (P < 0.01) or cisplatin (P < 0.0001) alone (Fig. 3A). In contrast, 1,25D₃ or cisplatin alone had no significant activity in SCC-DR cells (Fig. 3A), and the combination treatment resulted in a slight decrease in surviving fraction (Fig. 3A), suggesting critical role of 1,25D₃ in clonogenic cell kill.

---

**Figure 2.** 1,25D₃ sensitizes SCC cells to cisplatin treatment. A, SCC or SCC-DR cells were treated with 0 to 1 μg/mL cisplatin for 48 h, and cell viability was assessed by trypan blue exclusion assay. Mean ± SD of triplicate experiments. Representative of two independent experiments. B, SCC or SCC-DR cells were pretreated with vehicle control ethanol or 10 nmol/L 1,25D₃ for 24 h followed by 0.5 μg/mL cisplatin for 2 h. Cells were harvested after an additional 48 h of incubation. Cytotoxicity was examined by lactate dehydrogenase cytotoxicity detection kit. C, various dilutions of SCC or SCC-DR cells were plated in six-well tissue culture plates overnight. They were pretreated with ethanol or 10 nmol/L 1,25D₃ for 24 h and then incubated without further treatment or 0.5 μg/mL cisplatin for 2 h and subjected to in vitro clonogenic assay. Representative of two to three independent experiments. *, P < 0.00001 versus ethanol; #, P < 0.01 versus cDDP.
To determine the effects of 1,25D3 and cisplatin on tumor growth in vivo, SCC tumor-bearing mice were treated with saline, 0.25 μg/d 1,25D3 for 3 days, 6 mg/kg cisplatin on day 3, or the combination of 0.25 μg/d 1,25D3 for 3 days with 6 mg/kg cisplatin on day 3. This 1,25D3 dosing regimen was reported previously to maximize antitumor efficacy while minimizing toxicity or hypercalcemia (23). 1,25D3 or cisplatin alone exhibited tumor-inhibitory effects with 6 mg/kg cisplatin on day 3. This 1,25D3 dosing regimen was reported previously to maximize antitumor activity of cisplatin in the SCC model.

Mice in saline, 1,25D3, and cisplatin treatment groups had tumor regression compared with single agent (Fig. 3B). The combination of 1,25D3 and cisplatin resulted in enhanced antitumor activity of cisplatin in the SCC model.

**1,25D3 Promotes Cisplatin to Induce Apoptosis**

1,25D3 induces apoptosis in SCC cells (19, 21, 30). 1,25D3 and cisplatin treatment led to increased caspase-3 cleavage compared with single agent treatment (24). To further characterize 1,25D3 and cisplatin-induced apoptosis, DNA fragmentation was evaluated by Cell Death Detection ELISA. 1,25D3 enhanced DNA fragmentation in SCC cells compared with controls, whereas cisplatin did not induce apoptosis (Fig. 4A). The combination treatment resulted in a significantly (P < 0.01) higher level of apoptosis compared with 1,25D3 alone (Fig. 4A). Immunoblot analysis showed that 1,25D3 induced the cleavage of pro-caspase-8, -10, and -3 and poly(ADP-ribose) polymerase in SCC cells, whereas cisplatin did not (Fig. 4B). The combination treatment resulted in enhanced cleavage of pro-caspase-8 and -10 and poly(ADP-ribose) polymerase (Fig. 4B). None of these were observed in SCC-DR cells (Fig. 4B). Pro-caspase-9 was not cleaved by any treatment (Fig. 4B). These results suggest that 1,25D3 promotes cisplatin to induce apoptosis through a caspase-8/10-caspase-3 pathway in SCC cells.

**1,25D3-Augmented p73 Level Contributes to Cisplatin-Induced Growth Inhibition**

p73 is one of the p53 family members and may regulate apoptosis (10). Cisplatin has been reported to promote p73 protein accumulation in HCT116 cells (33). Therefore, we next examined whether 1,25D3 and cisplatin alter the protein levels of p73 and other p53 family members in SCC or SCC-DR cells. 1,25D3 alone or in combination with cisplatin enhanced full-length TAp73 (p73) levels in SCC cells as assessed by immunoblot analysis using a monoclonal antibody recognizing TAp73 but not reacting to ΔNp73 or p53 (Fig. 5A). In contrast, 1,25D3 resulted in reduced p53 protein level and the combination treatment also reduced p53 level (Fig. 5A). 1,25D3 alone or in combination with cisplatin also reduced p63 levels (Fig. 5A). Cisplatin did not affect the levels of p53, p63, or p73 in SCC cells (Fig. 5A). p53, p63, and p73 levels were not affected by any of the treatment in SCC-DR cells (Fig. 5A). To determine whether p73 accumulation contributes to 1,25D3 and cisplatin-induced growth inhibition, p73 was knocked down by siRNA. Because the endogenous p73 level was low, the efficiency of the p73 gene silencing was assessed by quantitative real-time PCR (Fig. 5B). Following siRNA transfection, SCC cells were further treated with ethanol or 10 nmol/L 1,25D3 for 24 h followed by 0.5 μg/mL cisplatin for 2 h and additional 6-day incubation for the in vitro clonogenic assay. siRNA-p73 significantly (P < 0.001) promoted the surviving fraction following the treatment of 1,25D3, cisplatin, or the combination (Fig. 5B). To determine whether augmenting p73 protein level further promotes the antiproliferative effects of 1,25D3 and cisplatin, we targeted a U-box-type E3/E4 ubiquitin ligase UFD2a, which promotes the degradation of p73 (34). Knocking down endogenous UFD2a by siRNA resulted in p73 accumulation in SCC cells (Fig. 5C). With siRNA-UFD2a transfection, 1,25D3 or combination treatment resulted in significantly reduced surviving fraction when...
compared with the nonspecific siRNA transfection (Fig. 5C). These data indicate that p73 contributes to the antiproliferative effects of 1,25D3 and cisplatin.

**p73 Contributes to 1,25D3 and Cisplatin-Induced Apoptosis**

To further elucidate the mechanisms for 1,25D3 and cisplatin-induced growth inhibition, whether p73 plays a role in apoptosis was examined. Following siRNA transfection, SCC cells were treated with 1,25D3 and/or cisplatin and DNA fragmentation was evaluated after an additional 48 h of incubation. siRNA-p73 transfection resulted in reduced DNA fragmentation induced by 1,25D3 alone or 1,25D3 and cisplatin compared with controls (Fig. 6A). These results indicate that p73 contributes to 1,25D3 and cisplatin-mediated apoptosis.

Altogether, our data showed that 1,25D3 sensitizes SCC cells to cisplatin-induced growth inhibition by the induction of p73, which promotes apoptosis through a caspase-8/10-caspase-3-dependent pathway (Fig. 6B).

**Discussion**

1,25D3 exerts antitumor effects *in vitro* and *in vivo* through inhibition of proliferation, induction of differentiation and apoptosis, and suppression of invasiveness of cancer cells (1). 1,25D3 has also been shown to synergistically or additively enhance the antitumor activities of several chemotherapeutic agents including carboplatin, cisplatin, docetaxel, and paclitaxel in prostate cancer, breast cancer, and SCC models (22, 23, 35, 36). The mechanisms for the enhanced antitumor effects are not well understood. 1,25D3 promoted caspase-3 cleavage when used in combination with cisplatin in SCC cells (24). 1,25D3-potentiated antitumor activity of paclitaxel is associated with reduced p21 in PC3 cells (22). In addition, 1,25D3 promotes docetaxel-induced growth inhibition by reducing multidrug resistance-associated protein 1 (36). 1,25D3 has been shown to enhance the cytotoxicity of carboplatin when used in clinical trials in patients with prostate cancer and advanced cancer (3).

To better understand the role of 1,25D3 in SCC cells, 1,25D3-resistant SCC variant was generated. SCC-DR cells showed resistance to 1,25D3-mediated growth inhibition and apoptosis and compromised VDR transcription activity and nongenomic signaling.

Cisplatin is a widely used chemotherapeutic agent. Unfortunately, drug resistance and toxic side effects limit its usage. Therefore, if tumor cells can be sensitized to cisplatin treatment, lower and thus more tolerated dose can be used in the treatment. Potential mechanisms for acquired resistance to cisplatin include drug inactivation by glutathione and metallothionein, enhanced DNA repair, decreased cisplatin accumulation, increased cisplatin...
adducts tolerance, and impaired apoptotic pathway (6). We showed previously that cellular concentration of cisplatin and cisplatin-DNA adducts did not change in response to 1,25D₃ and cisplatin combination treatment compared with cisplatin alone (24).

Although we showed previously that 1,25D₃ enhanced cisplatin antiproliferative effects and caspase-3 cleavage in SCC cells (24), the mechanisms for these effects are largely unknown. Our current study identified p73 as a target of 1,25D₃, the level of which is increased on 1,25D₃ treatment. We further show that p73 contributes to 1,25D₃ and cisplatin-mediated growth inhibition.

We show that SCC and SCC-DR cells are resistant to cisplatin, and 1,25D₃ sensitizes SCC cells to cisplatin-induced growth inhibition. Pretreatment with 1,25D₃ followed by cisplatin resulted in enhanced clonogenic cell kill in SCC, but not SCC-DR, cells in vitro and in vivo. 1,25D₃ in combination with cisplatin suppressed SCC tumor growth compared with either agent administered alone. This is in line with our previous data showing that a vitamin D analogue, Ro23-7553, increased tumor regrowth delay in a combination therapy with cisplatin when compared with either agent administered alone (23). Cisplatin alone does not induce apoptosis in SCC cells, whereas pretreatment with 1,25D₃ followed by cisplatin greatly enhances apoptosis compared with 1,25D₃ alone. Others have shown that damaged apoptotic pathway is one of the mechanisms for cisplatin resistance (6, 37). Impaired apoptosis may involve dysregulation and mutations of apoptosis-mediating molecules, which result in the inability of cells to detect DNA damage or to induce apoptosis (38–40). Therefore, SCC cells may be resistant to cisplatin treatment because cisplatin alone fails to induce apoptosis. When SCC cells are pretreated with 1,25D₃, the apoptotic pathway is restored and cisplatin is able to further promote apoptosis, which is indicated by enhanced

![Figure 5.](image-url)
cleavage of pro-caspases-8, 10 and poly(ADP-ribose) polymerase and increased DNA fragmentation.

Cisplatin may induce apoptosis through the regulation of p53 family member p73, which is regulated by DNA damage, oncogenes, and viral proteins (10). Cisplatin enhances p73 level in HCT116 cells by stabilizing p73 protein (33). In addition, cisplatin-mediated p73 accumulation contributes to cisplatin-induced apoptosis in Hep3B cells (41). When overexpressed, p73 promotes cisplatin-induced apoptosis in HeLa cells (42). Surprisingly, cisplatin did not induce p73 in SCC cells in this study, which may be one of the reasons why cisplatin alone failed to induce apoptosis in SCC cells. In contrast, 1,25D3 alone or in combination with cisplatin enhanced p73 protein level in SCC cells, most likely through increasing the stability of p73, because 1,25D3 did not alter the mRNA level of p73 as shown by quantitative real-time reverse transcription-PCR. 1,25D3 did not sensitize SCC-DR cells to cisplatin treatment. Further, p73, p53, and p63 levels were not affected by 1,25D3 in SCC-DR cells. These results indicate that 1,25D3 increased p73 protein level in SCC cells, which may be one of the reasons why cisplatin alone failed to induce apoptosis in SCC cells. In contrast, 1,25D3 alone or in combination with cisplatin enhanced p73 protein level in SCC cells, most likely through increasing the stability of p73, because 1,25D3 did not alter the mRNA level of p73 as shown by quantitative real-time reverse transcription-PCR. 1,25D3 did not sensitize SCC-DR cells to cisplatin treatment. Further, p73, p53, and p63 levels were not affected by 1,25D3 in SCC-DR cells. These results indicate that 1,25D3

signaling plays a critical role in potentiating the growth-inhibitory effects of cisplatin. When p73 is knocked down by siRNA approach, 1,25D3 and cisplatin-induced growth inhibition and apoptosis were suppressed. The endogenous protein level of p73 is very low in SCC cell cultures. The stability of p73 is regulated by the proteasome through ubiquitin-dependent and ubiquitin-independent pathways (43). UFD2a, a U-box-type ubiquitin protein ligase, has recently been reported to interact with and promote the degradation of p73 in an ubiquitin-independent manner (34). It does not affect the half-life of p53 (34). We took advantage of this phenomenon and augmented p73 protein level by siRNA-UFD2a. Increased p73 level promoted 1,25D3 and cisplatin-induced growth inhibition in SCC cells. These results suggest that p73 contributes to the antiproliferative and proapoptotic effects of 1,25D3 and cisplatin. In line with this concept, two recent studies show that p73 induction sensitizes tumor cells to therapies through enhanced apoptosis. CD154 sensitizes leukemia cells to fludarabine treatment via the activation of p73 and the consequent overcoming of the resistance to apoptosis (44). Endogenous expression of p73 was observed only in the radiosensitive cervical cancer cells, and p73 transfection in the radioresistant cells resulted in enhanced cellular sensitivity to radiation by increase of apoptosis (45).

The mechanisms for p73-induced apoptosis remain to be fully understood. p73 may induce apoptosis through the mitochondrial pathway by inducing Puma, which causes Bax mitochondrial translocation and cytochrome c release in Saos-2 cells (46). This apoptosis can be inhibited by the kinase inhibitor p57 kip2 is required for p73-mediated apoptosis in H1299 cells (47). Another study shows that p73 transfectionally promotes the expression of death receptor Fas and sensitizes cells to apoptosis via a caspase-dependent pathway (48). Further studies are required to elucidate the mechanisms for p73-mediated apoptosis in SCC cells.

In summary, the current study shows for the first time that 1,25D3 increased p73 protein level in SCC cells, which sensitized SCC cells to cisplatin-mediated growth inhibition and apoptosis. We propose that the combination of 1,25D3 and cisplatin as a strategy to overcome cisplatin resistance and dose limitation.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References


Mol Cancer Ther 2008;7(9). September 2008
1α,25-Dihydroxyvitamin D₃ potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model

Yingyu Ma, Wei-Dong Yu, Pamela A. Hershberger, et al.

Mol Cancer Ther 2008;7:3047-3055.

Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/7/9/3047

Cited articles
This article cites 48 articles, 22 of which you can access for free at:
http://mct.aacrjournals.org/content/7/9/3047.full#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
http://mct.aacrjournals.org/content/7/9/3047.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.